We spoke to Dr Vias Markides (Royal Brompton & Harefield NHS Foundation Trust, London, UK) at the 2019 Heart Rhythm Congress (HRC) in Birmingham, UK, for his thoughts on the customisation of atrial fibrillation treatment strategies and whether it is yet achievable in practice.
Speaker’s Disclosures: Vias Markides has a consultancy agreement with Biosense Webster.
1. Customisation of atrial fibrillation strategy – is this truly achievable yet? (0:09)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the Heart Rhythm Congress (HRC) 2019 in Birmingham, UK, October 2019 in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Atrial Fibrillation
Hugh Calkins: What can we look forward to at the Heart Rhythm Congress 2022
Prof Hugh Calkins (The Johns Hopkins University School of Medicine, Baltimore, Md, USA) explains how the Arrhythmia Alliance has been instrumental in empowering patients to become advocates for themselves, ask more questions and increase their knowledge. The Heart Rhythm Congress 2022 is back in person and a unique chance to bring patients and healthcare professionals […]
Renato Lopes, ESC 2022: Rivaroxaban for patients with atrial fibrillation and bioprosthetic mitral valves, the RIVER trial
The RIVER trial pre-specified analysis presented at ESC 2022 aimed to test the efficacy/safety of rivaroxaban compared to warfarin in patients with atrial fibrillation (AF) and bioprosthetic mitral valves, according to time of valve implantation. In this touchCARDIO interview, we speak with Professor Renato Lopes (Duke University Medical Center, Durham, NC, USA) to discuss non-vitamin […]
Wern Yew Ding, ESC 2022: The risk of adverse events despite anticoagulation in patients with atrial fibrillation, the GLORIA-AF registry (phase II/III results)
This post-hoc analysis, using data from the GLORIA-AF registry, aimed to evaluate the risk of adverse events, primarily the risk of ischaemic stroke, despite anticoagulation in patients with atrial fibrillation. Secondary outcomes were all-cause death, cardiovascular death and myocardial infarction. In this touchCARDIO interview, we speak with Dr Wern Yew Ding (Liverpool Heart and Chest […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!